PODD

Insulet is the clear category leader in tubeless insulin delivery via Omnipod, and Omnipod 5’s expanding eligibility (including planned U.S. updates in 1H26 for age 2+ T1D and adult T2D) reinforces a differentiated, software-enabled moat that is hard to replicate. The model benefits from recurring pod consumption once a patient is on therapy, supporting durable growth. Key competitive risk remains intensifying closed-loop competition from larger diabetes platforms, but Insulet’s simplicity and pharmacy-channel access continue to resonate.

Financially, momentum is strong: Q4 2025 revenue was $783.8M (+31% YoY) and FY2025 revenue was about $2.7B (+31%), with FY2025 gross margin 71.6% and adjusted EPS $4.97 (Q4 adjusted EPS $1.55). Cash was reported around $716M exiting Q4 2025, and the company expanded share repurchase authorization, supporting per-share compounding. Valuation is the main friction point: at roughly $203.73 per share and about 88x trailing P/E, the stock prices in years of strong execution.

Over the next 12 months, the thesis hinges on (1) delivering 2026 guidance (Omnipod segment +21–23% revenue growth; adjusted EPS growth >25%), (2) successful rollout/adoption of the 1H26 U.S. software updates, and (3) sustained international penetration. The key downside risks are pricing/reimbursement pressure and any stumbles in algorithm performance, supply, or competitive win rates that could compress the “premium growth” multiple.

Recommendation: HOLD. The business fundamentals and guidance trajectory look excellent, but the current valuation leaves limited margin of safety if growth moderates or competition drives higher spending.